

REMARKS

Claims 1, 6, 10,12-13, 15-16 and 18 are amended and claims 3, 4, 8 and 14 are canceled herein. Support is found, for example, at pages 10, 15-17 and 20-24. No new matter is presented.

The Office Action Summary sheet indicates that claims 2-16 and 18 are objected to. However, Applicants believe that the objection to claims 2-16 and 18 is incorrect as the claims are rejected under §§102 and 112. Clarification is requested for the record.

I. Response to Claim Rejection Under 35 U.S.C. § 102

Claims 1-4, 6, and 7 rejected under 35 U.S.C. §102(b) as allegedly being anticipated by Kori et al. (JP 2002-293764).

Claim 1 is amended herein to recite that K in formula (I) represents a C1-4 alkylene which may be substituted with 1 to 5 optional substituent(s) selected from the group consisting of methyl, a fluorine atom, hydroxy and oxo.

Kori et al does not disclose, teach or suggest a compound within the scope of formula (I) as recited in amended claim 1. Thus, Kori et al does not anticipate the claimed invention.

Accordingly Applicants respectfully request withdrawal of the §102 rejection.

II. Response to Claim Rejections Under 35 U.S.C. § 112

Claims 1-10, 12-16, and 18 are rejected under 35 U.S.C. §112, first paragraph, as allegedly failing to comply with the written description requirement.

Claims 1-10, 12-16, and 18 are rejected under 35 U.S.C. §112, second paragraph, as allegedly being indefinite. Specifically, the Examiner rejects the claims based on the use of the phrases “which may have substituents(s)”, “acidic group” and “spacer”.

Claim 16 is rejected under 35 U.S.C. §112, first paragraph, because the specification allegedly does not reasonably provide enablement for prevention and/or treatment of the claimed disorders.

Claim 1 is amended herein to further define the variables in formula (I) based on the features described in original claims 3, 4 and 8, preferred groups described in the specification and compounds in the working examples. Claim 1 is further amended by defining the terms “acidic group” and “spacer” based on the description in the specification at pages 17 and 15-16, respectively. Thus, Applicants submit that in view of the amendments to claim 1, the claimed invention is adequately described and one of ordinary skill in the art could readily ascertain the meaning and scope of the claimed invention.

Additionally, claim 16 is amended herein by deleting the phrase “prevention and/or”, and by limiting the EDG-2 related diseases to “urinary system disease”. In view thereof, Applicants submit that one of ordinary skill in the art would readily be able to practice the claimed invention based on the knowledge and skill in the art that urinary system diseases, such as those described at page 3, lines 3-16 of the specification, are controlled by LPA receptor antagonists and the exemplary compounds and biological examples provided in the specification at pages 136-139, which establish that the claimed compounds exert antagonistic activity to the LPA receptor (especially EDG-2).

Accordingly, Applicants respectfully request withdrawal of the §112 rejections.

III. Conclusion

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the


AMENDMENT UNDER 37 C.F.R. § 1.111
Application No.: 10/583,469

Attorney Docket No.: Q95536

Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565

CUSTOMER NUMBER

Date: February 20, 2009